Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amgen (NQ: AMGN )

272.11 +2.68 (+0.99%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,244,292
Open 276.97
Bid (Size) 271.00 (1)
Ask (Size) 272.98 (1)
Prev. Close 269.43
Today's Range 269.78 - 276.97
52wk Range 253.30 - 346.85
Shares Outstanding N/A
Dividend Yield 3.31%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Popular Ozempic, Wegovy Selected For Next Round Of Medicare Drug Price Negotiations
HHS adds 15 drugs to Medicare Part D price negotiations, targeting cost reductions under the Inflation Reduction Act. New prices aim to save billions by 2027. 
Via Benzinga
Topics Economy
Exposures Interest Rates
FDA Approves Amgen Treatment For Pretreated Colorectal Cancer With Certain Mutation
Amgen's Lumakras treatment, combined with Vectibix, is FDA-approved for KRAS G12C-mutated colorectal cancer. 
Via Benzinga
Exposures Product Safety

Performance

YTD
+4.95%
+4.95%
1 Month
+4.42%
+4.42%
3 Month
-14.09%
-14.09%
6 Month
-19.01%
-19.01%
1 Year
-11.60%
-11.60%

More News

Read More
2 Magnificent Stocks to Buy That Are Near Their 52-Week Lows
Via The Motley Fool
What Lies Ahead In 2025? Slower Growth, More Volatility
Via Talk Markets
Topics Economy Stocks / Equities
Exposures Economy
Got $5,000? These 3 Growth Stocks Are Trading Near Their 52-Week Lows.
Via The Motley Fool
Unpacking the Latest Options Trading Trends in Amgen
Via Benzinga
Peering Into Amgen's Recent Short Interest
Via Benzinga
Analyst Expectations For Amgen's Future
Via Benzinga
3 High-Yield Dividend Stocks to Buy in 2025
Via The Motley Fool
Obesity Treatments, M&A Activity To Take Center Stage During Upcoming JPM Healthcare Conference
Via Benzinga
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.
Via Investor's Business Daily
Topics Artificial Intelligence Government
Exposures Artificial Intelligence Political
UK Greenlights Amgen's Drug For Aggressive Lung Cancer In Pretreated Patients
Via Benzinga
Looking At Amgen's Recent Unusual Options Activity
Via Benzinga
Spotlight on Amgen: Analyzing the Surge in Options Activity
Via Benzinga
2 Excellent Dividend Stocks to Buy on the Dip
Via The Motley Fool
Prediction: These 3 Healthcare Stocks Will Soar in 2025
Via The Motley Fool
Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones?
Via The Motley Fool
Topics Stocks
Exposures US Equities
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
Via Benzinga
Dissecting Our Discipline
Via Talk Markets
Topics Stocks / Equities
Dogs Of The Dow: Top 10 High-Yield Stocks Offering Dividends Up To 6.8% In 2025
Via Benzinga
Topics Stocks
Exposures US Equities
3 Worst Performing Dow Jones Stocks In 2024
Via Talk Markets
Topics Stocks Stocks / Equities
Exposures US Equities
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Schwab US Dividend Equity ETF Reverses In December: What's Going On?
Via Benzinga
Topics ETFs
What's Going On With Amgen Stock On Friday?
Via Benzinga
Is Vertex Stock A Sell After Pain Drug Whiffs In Midstage Study?
Via Investor's Business Daily
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.